IN THE SPOTLIGHT

Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy

Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy

Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC

Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC

Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy

Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy

Giannis Mountzios: Discussing the Role of STK11/KEAP1/KRAS Mutations in Immune Modulation in NSCLC

Giannis Mountzios: Discussing the Role of STK11/KEAP1/KRAS Mutations in Immune Modulation in NSCLC

TROP2 ADC and PD-L1 mAb Show Promising Frontline Efficacy in NSCLC

TROP2 ADC and PD-L1 mAb Show Promising Frontline Efficacy in NSCLC

Refining Treatment Timelines and Immunotherapy Strategies in Early-Stage NSCLC: Jonathan Thompson, MD, MS

Refining Treatment Timelines and Immunotherapy Strategies in Early-Stage NSCLC: Jonathan Thompson, MD, MS

FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug

FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug

文献速递丨ADC治疗HER2突变晚期NSCLC,DESTINY-Lung02研究数据更新_腾讯新闻

文献速递丨ADC治疗HER2突变晚期NSCLC,DESTINY-Lung02研究数据更新_腾讯新闻

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC